Intelligent Medicine Acquisition Corp.
We intend to focus our search on life science companies that are using artificial intelligence (“AI”), machine learning (“ML”) and big data to create and power a new model of drug discovery through research and development that is far faster, less expensive and more predictable than the decades-old system of drug development we still follow today.
With a broadening set of applications for biotechnology that includes research tools and infrastructure, diagnostics, therapeutics, data, and industrial outputs, we believe the life sciences sector offers compelling opportunities for investors who possess a broad overview and understand the trends and themes.
Our CEO is Gregory Simon, the former executive director of the White House Cancer Moonshot Task Force.
(Note: Intelligent Medicine Acquisition Corp. upsized its SPAC IPO at pricing on Nov. 4, 2021, to 18 million units, up from 15 million in the prospectus, at $10 each to raise $180 million.)
|Address||9001 Burdette Rd. Bethesda, MD 20817|
|Phone Number||(202) 905-5834|
|View Prospectus:||Intelligent Medicine Acquisition Corp.|
|Revenues||$0 mil (last 12 months)|
|Net Income||$0 mil (last 12 months)|
|Price range||$10.00 - $10.00|
|Est. $ Volume||$180.0 mil|
|Manager / Joint Managers||Cantor Fitzgerald|
|Expected To Trade:||11/5/2021|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|